Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Left ventricular (LV) thrombus is a common problem that is encountered in patients who
survived from a large myocardial infarction, and distal systemic embolization is the main
issue in these patients due to its major clinical consequences especially cerebrovascular
stroke.
Novel oral anticoagulants (NOACs) are now used safely in nonvalvular atrial fibrillation,
these agents were shown to be at least as effective as Vitamin K antagonists (VKA) such as
warfarin in prevention of systemic embolism, while having an improved safety profile with
less bleeding risk. However, the data about their usage for LV thrombi instead of the
commonly used VKA are still lacking except for case reports and small case series.
The proposed aim of this randomized observational clinical trial is to assess the efficacy of
the conventional anticoagulation in the form of warfarin and NOACs in the form of rivaroxaban
in the treatment of LV thrombus.
Phase:
Phase 3
Details
Lead Sponsor:
The Young Investigator Group of Cardiovascular Research